Discussion of preliminary results from an ongoing phase 1 clinical trial studying the safety and efficacy of novel BCL2 inhibitor BGB-11417 alone and in combination with the next-generation BTK inhibitor zanubrutinib.
The short answer is that it is certainly beginning to look that way for a lucky few. This month celebrated the 10th CAR-T anniversary of Doug Olson, who remains cancer-free with persistent CAR-T cells that still play WHACK-A-MOLE should any cancerous CLL cells dare to reappear.
CLL Society brings ASH 2021 to you! The American Society of Hematology Annual Meeting had important research presented and now Drs. Anthony Mato and Brian Koffman will highlight findings that you should know when considering future treatment options.
CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL/SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You can learn more about CAR-T therapy in this easy-to-understand CAR-T brochure that can be viewed in this digital flipbook format
At the annual meeting of the American Society of Hematology (ASH) 2020, our own Steven Bloom interviewed Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. They discussed the SEQUOIA trial, which is a phase 3 trial testing
Dr. Matt Davids of Dana Farber presented this abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021) that updated the results of combining two different oral targeted therapies that both block B-cell receptor (BCR) signaling: Ibrutinib through BTK inhibition and umbralisib, an experimental inhibitor of PI3K.